Sglt2 Inhibitors Market Current And Projected Size In Terms Of Volume And Value 20162024 | Latest News RSS feed

Sglt2 Inhibitors Market Current And Projected Size In Terms Of Volume And Value 20162024 - Latest News

AstraZeneca Group plc (AZN) CEO Pascal Soriot on Q3 2018 Results - Earnings Call Transcript

Farxiga delivered sales of 994 million in the year to date with 32% growth, maintaining volume market ... term of health care cost. It's a major problem. So if we, in diabetes, can establish that ... read more

Sirona Biochem Corporation-CEO's Report on Progress

We raised $600,000 in debt which gave us the financial runway to grow the value ... term goals include setting up future pipeline projects and growing our R&D infrastructure. In the next 30 months we ... read more

Inovalon Reports Fourth Quarter and Full Year 2016 Results

Feb. 22, 2017 (GLOBE NEWSWIRE) -- Inovalon (Nasdaq:INOV), a leading technology company providing advanced, cloud-based platforms empowering a data-driven transformation from volume-based to value-base... read more

Looking for another news?

ARIPO approves Sirona Biochem's patents for diabetes and skin whitening applications

This patent is one of seven that have been issued to TFChem, and includes the SGLT2 inhibitor and skin whitening technology ... Diabetes is a global epidemic. The market for type 2 diabetes drugs coul... read more

Merck Announces Second-Quarter 2017 Financial Results

“The company continues to invest in innovative science that addresses the critical needs of population health, which benefits patients while creating long-term value for shareholders ... an investigat... read more

Lilly Reports Strong First-Quarter 2018 Results, Raises EPS Guidance

New pharmaceutical products, including Trulicity, Cyramza, Basaglar, Jardiance, Taltz, Lartruvo, Olumiant, and Verzenio, represented 25 percent of total revenue and drove 11 percent volume ... managem... read more

Diabetes UK, March 2013, Manchester, UK

Held over three days in an inevitably wet Manchester, UK, and titled ‘The Future of Diabetes ... (especially stroke), renal function and bone safety. The SGLT-2 inhibitors may prove to be of value in ... read more

Pfizer's CEO Discusses Q4 2013 Results - Earnings Call Transcript

We initiated a Phase 3 program with our partner Merck for ertugliflozin, our SGLT2 inhibitor ... value for shareholders through disciplined capital allocation and our commercial businesses have perfor... read more

Understanding employment contracts: What to know before you sign

For an NP entering the market, a new position secured ... the contract should be written in explicit terms. For example, it could mean that in addition to the physical and professional duties of the p... read more

AstraZeneca up after diabetes combo passes phase III

Astra’s Elisabeth Björk added: “With DURATION-8, AstraZeneca is the first company to highlight the results of combining a GLP-1 receptor agonist and SGLT-2 inhibitor as a potential treatment alternati... read more

FeedsRSS Created by. Full RSS Feed | Privacy Policy | Contact Us